BioCardia Reports Q3 2026 Net Loss of $1.8 Million

BioCardia reported a Q3 2026 net loss of $1.8M, up from $1.5M a year earlier. Cash reserves were $2.2M, with $1.7M used in operations. The company made progress on CardiAMP, Helix, and Heart3D programs, with key regulatory milestones expected in 2027.

Original reporting
Published Nov 12, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BioCardia Reports Q3 2026 Net Loss of $1.8 Million — source image
Decision brief

The 30-second read

$BCDABearishLow
01

Why it matters

The disclosed loss and cash burn highlight financing needs, but progress on regulatory submissions may offer a catalyst later in 2027.

02

Market read

Micro‑cap earnings with a modest loss; likely limited immediate market movement but important for investors tracking biotech cash‑flow risk.

03

What to watch

Potential cash infusion from partnership with CART‑Tech or future grant funding could mitigate liquidity concerns.

Relevance 6/10Novelty 6/10Timing: after-hours

Background

BioCardia is a clinical‑stage biotech developing cardiac therapies. The Q3 filing provides the latest financial snapshot and updates on its CardiAMP, Helix, and Heart3D programs.

Company-level read

Ticker impact

$BCDABearishMedium confidence
Context

BioCardia disclosed Q3 2026 net loss of $1.8M and cash position, the first public filing of these results.

Expected impact

likely downward pressure as investors price the widening loss and limited liquidity.

Evidence & confidence

Micro‑cap earnings with a net loss and minimal cash typically trigger sell‑offs.

Market effects

Limited impact on the broader biotech sector; results reflect early‑stage development risk.

Primarily relevant to US small‑cap investors; no broader regional effect.

Minimal global relevance.

Counterpoint

If the upcoming regulatory submissions succeed, the short‑term loss may be outweighed by long‑term upside.

Key entities

  • BioCardia, Inc.

    Clinical‑stage biotech reporting Q3 2026 results.

  • CART‑Tech

    Collaborator on the Heart3D platform.

Related articles

$BCDAMed

BioCardia Inc (BCDA) (Q3 2026) Earnings Call Highlights: Japan Shonin Submission Advances

BioCardia Inc (BCDA) reported Q3 2026 earnings, highlighting progress in Japan's Shonin submission for CardiAMP Cell Therapy, expected within months. CEO Peter Altman discussed partnerships, regulatory pathways, and clinical trial updates. The company reported $1.7M in net cash used in operations, with $2.2M in cash reserves. Key catalysts include FDA feedback on the Helix catheter system and potential gene therapy partnerships.

$BCDAMedAI 8/10

BioCardia’s CardiAMP Completes Japan Pre-Market Consultation, First Cardiac Cell Therapy to Do So

BioCardia (BCDA) completed Japan's PMDA consultation for its CardiAMP Cell Therapy System, positioning it for a marketing approval application. The therapy, which uses a patient's own bone marrow cells, aims to treat heart damage. BioCardia targets a formal submission by late 2026 and commercial revenue by 2028. The company's Phase 3 trial showed significant improvements in a subgroup of patients with elevated NTproBNP levels, which PMDA has reviewed positively.

$BCDAMed

BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application SUNNYVALE, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. (NASDAQ: BCDA) , a global le

$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.